Overview

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Status:
Not yet recruiting

Trial end date:
2026-04-20

Target enrollment:

Participant gender:

Summary

This study will explore the efficacy and safety of tislelizumab (PD1 inhibitor) combined with DisitamabVedotin (ADC) and pyrotinib maleate (TKI) in the treatment of HER2-positive or mutated advanced colorectal cancer who have failed standard therapy .

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Zhengzhou University

Collaborators:

BeiGene
Jiangsu Hengrui Pharmaceutical Co., Ltd.
RemeGen Co., Ltd.

Treatments:

Maleic acid